Introducing in-kind contributions
IHI’s funding is based on a model of blended finance, where EU funding is matched by contributions from our industry partners and (in some projects) other organisations such as philanthropic foundations.
The majority (around 90%) of the industry contribution to IMI and IHI projects is ‘in-kind’. In-kind contributions include scientific and regulatory expertise; unique data, assets and compounds; and access to state-of-the-art research infrastructure and cutting-edge technology. Crucially, these private sector in-kind contributions complement the skills, expertise and resources brought into the project by the ‘public’ partners such as universities and patient organisations.
About this webinar
During this webinar, representatives of IMI and IHI projects:
- presented concrete examples of different kinds of in-kind contributions;
- explained how in-kind contributions allowed the projects to deliver results that would not have been possible otherwise;
- demonstrated how in-kind contributions incentivise the uptake and exploitation of project results;
- described how in-kind contributions drive additional activities within and across companies by combining outcomes from several projects.
Speakers
- Geert D’Haens from Amsterdam UMC and Scott Wagers from BioSci Consulting will represent the IHI project INTERCEPT.
- Paula Curras from Medtronic will present the IHI project GRACE.
- Lutgart Overbergh from KU Leuven will discuss the IMI project INNODIA.
- Jorg Blankenstein from Sanofi will present the IMI project 3TR.